SRP19

Summary

SRP19 (signal recognition particle 19, HGNC:11300) is a protein-coding gene on chromosome 5q22.2, encoding Signal recognition particle 19 kDa protein (P09132). Component of the signal recognition particle (SRP) complex, a ribonucleoprotein complex that mediates the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). It is a common-essential gene (DepMap: required in 98.8% of cancer cell lines).

Enables 7S RNA binding activity. Contributes to ribosome binding activity. Predicted to be involved in SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition. Located in cytosol; nuclear body; and nucleolus. Part of signal recognition particle, endoplasmic reticulum targeting.

Source: NCBI Gene 6728 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neutropenia (Moderate, GenCC)
• Clinical variants (ClinVar): 30 total — 2 pathogenic
• Phenotypes (HPO): 31
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 98.8% of screened cell lines (common-essential)
• MANE Select transcript: NM_003135

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11300
Approved symbol	SRP19
Name	signal recognition particle 19
Location	5q22.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000153037
Ensembl biotype	protein_coding
OMIM	182175
Entrez	6728

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 8 protein_coding, 4 retained_intron, 1 nonsense_mediated_decay

ENST00000282999, ENST00000391338, ENST00000445150, ENST00000503445, ENST00000504696, ENST00000505459, ENST00000506987, ENST00000506997, ENST00000509024, ENST00000515463, ENST00000515755, ENST00000621420, ENST00000937586

RefSeq mRNA: 5 — MANE Select: NM_003135 NM_001204193, NM_001204194, NM_001204196, NM_001204199, NM_003135

CCDS: CCDS4108, CCDS56375, CCDS56376, CCDS75286, CCDS87319

Canonical transcript exons

ENST00000505459 — 5 exons

Exon	Start	End
ENSE00001386052	112861287	112861417
ENSE00002032363	112867404	112869788
ENSE00003609317	112864457	112864528
ENSE00003637772	112864621	112864732
ENSE00003823522	112862508	112862583

Expression profiles

Bgee: expression breadth ubiquitous, 169 present calls, max score 98.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 57.0569 / max 908.5516, expressed in 1821 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58011	57.0502	1821
58012	0.0067	3

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	98.06	gold quality
body of pancreas	UBERON:0001150	97.74	gold quality
islet of Langerhans	UBERON:0000006	96.69	gold quality
left adrenal gland	UBERON:0001234	96.69	gold quality
left adrenal gland cortex	UBERON:0035825	96.69	gold quality
right adrenal gland cortex	UBERON:0035827	96.59	gold quality
left lobe of thyroid gland	UBERON:0001120	96.56	gold quality
right adrenal gland	UBERON:0001233	96.49	gold quality
right lobe of liver	UBERON:0001114	96.29	gold quality
adrenal tissue	UBERON:0018303	96.29	gold quality
right lobe of thyroid gland	UBERON:0001119	96.16	gold quality
minor salivary gland	UBERON:0001830	95.97	gold quality
cortical plate	UBERON:0005343	95.91	gold quality
smooth muscle tissue	UBERON:0001135	95.89	gold quality
vermiform appendix	UBERON:0001154	95.88	gold quality
left coronary artery	UBERON:0001626	95.87	gold quality
metanephros cortex	UBERON:0010533	95.83	gold quality
lower esophagus	UBERON:0013473	95.69	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.69	gold quality
ganglionic eminence	UBERON:0004023	95.66	gold quality
stromal cell of endometrium	CL:0002255	95.65	gold quality
embryo	UBERON:0000922	95.65	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.63	gold quality
body of stomach	UBERON:0001161	95.62	gold quality
ascending aorta	UBERON:0001496	95.61	gold quality
thoracic aorta	UBERON:0001515	95.61	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.58	gold quality
anterior cingulate cortex	UBERON:0009835	95.58	gold quality
mucosa of transverse colon	UBERON:0004991	95.57	gold quality
left uterine tube	UBERON:0001303	95.53	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	39.18
E-ANND-3	yes	12.82
E-MTAB-6142	no	167.85

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

48 targeting SRP19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 98.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 8)

• 1.8 angstrom resolution crystal structure of human SRP19 in complex with its primary binding site on helix 6 of SRP RNA was determined (PMID:11641499)
• Structure of the SRP19 RNA complex (PMID:12050674)
• crystal structure of a human SRP ternary complex consisting of SRP19, the M domain of SRP54 and the S domain of 7SL RNA (PMID:12244299)
• Data show that the presence of SRP54 during SRP19-RNA assembly dramatically alters the folding energy landscape to create a non-native folding pathway that leads to an aberrant SRP19-RNA conformation. (PMID:17434535)
• crystal structures of a crenarchaeal and the all-human SRP19-signal recognition particle RNA binary complexes presented here show that the asymmetric loop is bulged out in both binary complexes. (PMID:20179341)
• anti-SRP19 antibody is highly expressed in muscle tissues of patients with autoimmune necrotizing myopathy. (PMID:27525944)
• The crystal structures of the SRP68 protein-binding domain (PBD) in complex with SRP72-PBD and of the SRP72-RBD bound to the SRP S domain (SRP RNA, SRP19 and SRP68) detailing all interactions of SRP72 within SRP have been presented. (PMID:27899666)
• Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes. (PMID:36223592)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	srp19	ENSDARG00000035699
mus_musculus	Srp19	ENSMUSG00000014504
rattus_norvegicus	Srp19	ENSRNOG00000020204
drosophila_melanogaster	Srp19	FBGN0015298
caenorhabditis_elegans	F37F2.2	WBGENE00018159

Protein

Protein identifiers

Signal recognition particle 19 kDa protein — P09132 (reviewed: P09132)

All UniProt accessions (6): P09132, A0A087WWU9, A0A087WYR0, A0A2R8Y4M3, A0A2U3TZN1, D6RBG4

UniProt curated annotations — full annotation on UniProt →

Function. Component of the signal recognition particle (SRP) complex, a ribonucleoprotein complex that mediates the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). Binds directly to 7SL RNA. Mediates binding of SRP54 to the SRP complex.

Subunit / interactions. Component of a signal recognition particle complex that consists of a 7SL RNA molecule of 300 nucleotides and 6 protein subunits: SRP72, SRP68, SRP54, SRP19, SRP14 and SRP9. Interacts with IPO5, IPO7, IPO8, KPNB1 and TNPO1. Interactions with IPO8 and TNPO1 may be involved in SRP19 import into the nucleus.

Subcellular location. Cytoplasm. Nucleus. Nucleolus. Nucleoplasm.

Similarity. Belongs to the SRP19 family.

Isoforms (3)

UniProt ID	Names	Canonical?
P09132-1	1	yes
P09132-2	2
P09132-3	3

RefSeq proteins (5): NP_001191122, NP_001191123, NP_001191125, NP_001191128, NP_003126* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002778	Signal_recog_particle_SRP19	Family
IPR036521	SRP19-like_sf	Homologous_superfamily

Pfam: PF01922

UniProt features (21 total): helix 7, strand 6, turn 2, splice variant 2, chain 1, region of interest 1, compositionally biased region 1, sequence variant 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
1JID	X-RAY DIFFRACTION	1.8
7QWQ	ELECTRON MICROSCOPY	2.83
1MFQ	X-RAY DIFFRACTION	3.1
7NFX	ELECTRON MICROSCOPY	3.2
5M73	X-RAY DIFFRACTION	3.4
4P3E	X-RAY DIFFRACTION	3.5
3KTV	X-RAY DIFFRACTION	3.8
2J37	ELECTRON MICROSCOPY	8.7
1RY1	ELECTRON MICROSCOPY	12

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P09132-F1	86.93	0.75

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1799339	SRP-dependent cotranslational protein targeting to membrane
R-HSA-392499	Metabolism of proteins
R-HSA-72766	Translation

MSigDB gene sets: 262 (showing top): MORF_MBD4, YAGI_AML_WITH_INV_16_TRANSLOCATION, MORF_RAB5A, GOBP_PROTEIN_TARGETING, MORF_RAD21, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, MODULE_149, BROWNE_HCMV_INFECTION_12HR_UP, MORF_PSMC2, PUJANA_CHEK2_PCC_NETWORK, WEI_MYCN_TARGETS_WITH_E_BOX, MORF_SKP1A, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE

GO Biological Process (3): cotranslational protein targeting to membrane (GO:0006613), SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition (GO:0006617), SRP-dependent cotranslational protein targeting to membrane (GO:0006614)

GO Molecular Function (4): RNA binding (GO:0003723), 7S RNA binding (GO:0008312), protein binding (GO:0005515), ribosome binding (GO:0043022)

GO Cellular Component (9): nucleolus (GO:0005730), signal recognition particle, endoplasmic reticulum targeting (GO:0005786), cytosol (GO:0005829), nuclear body (GO:0016604), signal recognition particle (GO:0048500), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Translation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
nuclear lumen	2
intracellular membraneless organelle	2
cytoplasm	2
protein targeting to membrane	1
SRP-dependent cotranslational protein targeting to membrane	1
protein-containing complex assembly	1
translation	1
cotranslational protein targeting to membrane	1
protein targeting to ER	1
nucleic acid binding	1
RNA binding	1
binding	1
ribonucleoprotein complex binding	1
signal recognition particle	1
nucleoplasm	1
ribonucleoprotein complex	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
protein-containing complex	1

Protein interactions and networks

STRING

1732 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SRP19	SRP14	P37108	999
SRP19	SRP9	P49458	999
SRP19	SRP68	Q9UHB9	999
SRP19	SRP72	O76094	999
SRP19	SRP54	P13624	999
SRP19	SRPRA	P08240	730
SRP19	REEP5	Q00765	719
SRP19	APC	P25054	710
SRP19	SRPRB	Q9Y5M8	690
SRP19	SEC61A1	P38378	642
SRP19	APOBEC3G	Q9HC16	579
SRP19	RPL23A	P29316	578
SRP19	SPCS1	Q9Y6A9	573
SRP19	SEC62	Q99442	571
SRP19	SEC63	Q9UGP8	538

IntAct

71 interactions, top by confidence:

A	B	Type	Score
MED17	MED19	psi-mi:“MI:0914”(association)	0.840
SRP9	SRP72	psi-mi:“MI:0914”(association)	0.730
XPC	CETN3	psi-mi:“MI:0914”(association)	0.730
SRP68	SRP72	psi-mi:“MI:0914”(association)	0.730
SRP19	SRP68	psi-mi:“MI:0915”(physical association)	0.720
rep	MPHOSPH10	psi-mi:“MI:0914”(association)	0.660
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
SRP72	SRP19	psi-mi:“MI:0914”(association)	0.530
SRP68	MAGEB2	psi-mi:“MI:0914”(association)	0.530
CST1	CTSV	psi-mi:“MI:0914”(association)	0.530
Srp54	SRP19	psi-mi:“MI:0407”(direct interaction)	0.440
MAPK8IP2	SRP19	psi-mi:“MI:0915”(physical association)	0.370
SRP19	E7	psi-mi:“MI:0915”(physical association)	0.370
HSCB	SRP19	psi-mi:“MI:0915”(physical association)	0.370
Cep78	ING5	psi-mi:“MI:0914”(association)	0.350
Srp72		psi-mi:“MI:0914”(association)	0.350
NCBP3	ALYREF	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
SOD1	NPEPPSL1	psi-mi:“MI:0914”(association)	0.350
TRADD	HNRNPCL2	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
SRP68	SRP72	psi-mi:“MI:0914”(association)	0.350
FGFR1	POLRMT	psi-mi:“MI:0914”(association)	0.350
FGFR1	MRPS14	psi-mi:“MI:0914”(association)	0.350
ATRIP	HMGN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (296): SRP19 (Co-fractionation), SRP19 (Reconstituted Complex), SRP19 (Two-hybrid), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Affinity Capture-MS), SRP19 (Negative Genetic), SRP19 (Negative Genetic), SRP19 (Positive Genetic), SRP19 (Positive Genetic)

ESM2 similar proteins: A0A1D8PHF5, A3CWZ5, A7I9I7, B8GEU5, G1SHG0, J9PAS6, O18602, O61749, O65071, P09132, P0C2H8, P0C2H9, P0CX31, P0CX32, P45841, P46290, P51420, P62899, P62900, P62901, P62902, Q1KSC7, Q22DH9, Q2FS98, Q3ZBG7, Q54XB5, Q56JX3, Q5RBR1, Q5RBR9, Q6FWF4, Q6NUH0, Q757D7, Q75K27, Q7KF90, Q8LC83, Q8PYQ4, Q8SSC8, Q8TIN3, Q90YT7, Q9D7A6

Diamond homologs: A0B5U7, A1RS22, A2BJ20, A3DNY0, A4FX62, A4WLN0, A5UNC8, A6UPB8, A6USX5, A6VG52, A7IAR2, A8AAJ8, A9AAJ9, B0R5G1, B8D570, B9LUG2, D4GW40, J9PAS6, O13475, O14415, O26267, O29010, O61749, O74102, P09132, P29478, P41922, P49964, Q0W2Z9, Q12U87, Q18K21, Q2NF32, Q3IPF4, Q3ZBG7, Q46D06, Q554G7, Q58440, Q5RBR1, Q5V5S9, Q6BM93

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
SRP19	“up-regulates activity”	SRP72	binding
SRP19	“up-regulates activity”	SRP68	binding
SRP19	“up-regulates activity”	SRP54	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 85 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SRP-dependent cotranslational protein targeting to membrane	9	18.8×	3e-07
Response of EIF2AK4 (GCN2) to amino acid deficiency	5	11.6×	9e-03
Translation	8	10.3×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	6	16.1×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	14
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3246383	NC_000005.9:g.(?112173930)(112310702_?)del	Pathogenic
810839	NM_003135.3(SRP19):c.189+5G>A	Pathogenic

SpliceAI

1966 predictions. Top by Δscore:

Variant	Effect	Δscore
5:112861415:CAG:C	donor_loss	1.0000
5:112861416:AG:A	donor_loss	1.0000
5:112861417:GG:G	donor_loss	1.0000
5:112864615:T:G	acceptor_gain	1.0000
5:112864696:G:GT	donor_gain	1.0000
5:112864733:G:GG	donor_gain	1.0000
5:112887010:CTTA:C	donor_loss	1.0000
5:112887011:TTACC:T	donor_loss	1.0000
5:112887012:TACCT:T	donor_loss	1.0000
5:112887014:CCTT:C	donor_gain	1.0000
5:112887179:CCACA:C	acceptor_gain	1.0000
5:112887180:CACA:C	acceptor_gain	1.0000
5:112887180:CACAC:C	acceptor_gain	1.0000
5:112887182:CA:C	acceptor_gain	1.0000
5:112887184:C:CC	acceptor_gain	1.0000
5:112861414:ACAG:A	donor_loss	0.9900
5:112861417:GGT:G	donor_loss	0.9900
5:112861418:GT:G	donor_loss	0.9900
5:112861418:GTGG:G	donor_loss	0.9900
5:112861419:T:G	donor_loss	0.9900
5:112864456:GGCT:G	acceptor_gain	0.9900
5:112864609:C:CA	acceptor_gain	0.9900
5:112876429:A:AG	acceptor_gain	0.9900
5:112876430:G:GG	acceptor_gain	0.9900
5:112876430:GT:G	acceptor_gain	0.9900
5:112878844:T:C	acceptor_gain	0.9900
5:112878844:T:TC	acceptor_gain	0.9900
5:112878847:T:C	acceptor_gain	0.9900
5:112878847:T:TC	acceptor_gain	0.9900
5:112887181:ACA:A	acceptor_gain	0.9900

AlphaMissense

937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:112862560:G:A	G32R	1.000
5:112862560:G:C	G32R	1.000
5:112862561:G:A	G32E	1.000
5:112862561:G:T	G32V	1.000
5:112862564:G:C	R33T	1.000
5:112862564:G:T	R33M	1.000
5:112862565:G:C	R33S	1.000
5:112862565:G:T	R33S	1.000
5:112864461:T:A	V41D	1.000
5:112864470:C:A	P44H	1.000
5:112864673:G:C	R81T	1.000
5:112864674:A:C	R81S	1.000
5:112864674:A:T	R81S	1.000
5:112864676:T:A	V82D	1.000
5:112864682:T:A	V84D	1.000
5:112867437:T:A	I112K	1.000
5:112867446:T:C	L115P	1.000
5:112867455:G:C	R118T	1.000
5:112867455:G:T	R118M	1.000
5:112867456:G:C	R118S	1.000
5:112867456:G:T	R118S	1.000
5:112862509:T:C	F15L	0.999
5:112862511:T:A	F15L	0.999
5:112862511:T:G	F15L	0.999
5:112862521:T:G	Y19D	0.999
5:112862538:T:A	N24K	0.999
5:112862538:T:G	N24K	0.999
5:112862563:A:G	R33G	0.999
5:112864457:G:C	A40P	0.999
5:112864458:C:A	A40D	0.999

dbSNP variants (sampled 300 via entrez): RS1000020527 (5:112862366 C>A,G,T), RS1000051314 (5:112895273 G>A), RS1000064853 (5:112872640 A>G), RS1000095584 (5:112872310 C>G), RS1000307309 (5:112877842 T>A), RS1000346703 (5:112888905 G>A,C), RS1000363317 (5:112862165 GC>G), RS1000485526 (5:112863150 C>G), RS1000495229 (5:112866435 C>G,T), RS1000573742 (5:112868097 C>A,G,T), RS1000583895 (5:112877543 G>A), RS1000585214 (5:112881974 G>T), RS1000622647 (5:112871779 A>C,G), RS1000641730 (5:112861268 G>A,T), RS1000707290 (5:112894701 A>G)

Disease associations

OMIM: gene MIM:182175 | disease phenotypes: MIM:175100, MIM:202700, MIM:260400

GenCC curated gene-disease

Disease	Classification	Inheritance
neutropenia	Moderate	Autosomal recessive

Mondo (4): familial adenomatous polyposis 1 (MONDO:0021056), severe congenital neutropenia (MONDO:0018542), Shwachman-Diamond syndrome 1 (MONDO:0044204), neutropenia (MONDO:0001475)

Orphanet (1): Severe congenital neutropenia (Orphanet:42738)

HPO phenotypes

31 total (30 of 31 shown, HPO-id order):

HPO	Term
HP:0000155	Oral ulcer
HP:0000230	Gingivitis
HP:0000704	Periodontitis
HP:0000938	Osteopenia
HP:0001028	Hemangioma
HP:0001581	Recurrent skin infections
HP:0001875	Decreased total neutrophil count
HP:0001880	Increased total eosinophil count
HP:0001888	Decreased total lymphocyte count
HP:0001909	Leukemia
HP:0001915	Aplastic anemia
HP:0001945	Fever
HP:0002014	Diarrhea
HP:0002027	Abdominal pain
HP:0002090	Pneumonia
HP:0002718	Recurrent bacterial infections
HP:0002863	Myelodysplasia
HP:0003453	Antineutrophil antibody positivity
HP:0004429	Recurrent viral infections
HP:0004798	Recurrent infection of the gastrointestinal tract
HP:0004808	Acute myeloid leukemia
HP:0005425	Recurrent sinopulmonary infections
HP:0006480	Premature loss of teeth
HP:0006721	Acute lymphoblastic leukemia
HP:0011107	Recurrent aphthous stomatitis
HP:0012311	Increased total monocyte count
HP:0012384	Rhinitis
HP:0025439	Pharyngitis
HP:0025452	Pyoderma gangrenosum
HP:0100658	Cellulitis

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009503	Neutropenia	C15.378.243.750.184.564; C15.378.553.546.184.564

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295704 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs495794	Efficacy	3	citalopram;fluoxetine;paroxetine;sertraline	Major Depressive Disorder

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs495794	SRP19	3	2.50	1	citalopram;fluoxetine;paroxetine;sertraline

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
Particulate Matter	decreases reaction, increases expression, affects cotreatment, increases abundance	2
FR900359	decreases phosphorylation	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects expression	1
methylselenic acid	decreases expression	1
titanium dioxide	decreases expression	1
tetrahydropalmatine	decreases expression	1
beta-lapachone	increases expression	1
sodium arsenite	decreases expression	1
M-VAC protocol	decreases response to substance	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	increases expression	1
bisphenol B	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
bisphenol AF	increases expression	1
Irinotecan	affects cotreatment, decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Vehicle Emissions	decreases reaction, increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Fluorouracil	affects cotreatment, decreases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Ivermectin	decreases expression	1
Ozone	affects expression, increases abundance	1
Phthalic Acids	increases methylation	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1
Ribonucleotides	affects binding	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118615	Binding	Binding affinity to SRP19 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

205 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00125723	PHASE4	COMPLETED	FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
NCT00194857	PHASE4	TERMINATED	Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
NCT00257790	PHASE4	COMPLETED	The Tobramycin Study
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00686543	PHASE4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01114165	PHASE4	COMPLETED	Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
NCT01135589	PHASE4	UNKNOWN	Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation
NCT01571518	PHASE4	UNKNOWN	Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy
NCT02621905	PHASE4	COMPLETED	Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
NCT02967341	PHASE4	UNKNOWN	Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients
NCT04009941	PHASE4	COMPLETED	Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04904614	PHASE4	COMPLETED	Letermovir Use in Heart Transplant Recipients
NCT05626530	PHASE4	RECRUITING	Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
NCT06145321	PHASE4	ACTIVE_NOT_RECRUITING	Continuous Versus Bolus Administration of G-CSF in Children With Cancer
NCT00140894	PHASE4	TERMINATED	A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
NCT01859637	PHASE4	TERMINATED	Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia
NCT00001338	PHASE3	COMPLETED	A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00002658	PHASE3	UNKNOWN	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
NCT00002719	PHASE3	COMPLETED	Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia
NCT00003739	PHASE3	COMPLETED	Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
NCT00020865	PHASE3	UNKNOWN	Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
NCT00035594	PHASE3	COMPLETED	Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
NCT00044486	PHASE3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00107081	PHASE3	TERMINATED	Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting
NCT00445497	PHASE3	UNKNOWN	Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia
NCT00529282	PHASE3	TERMINATED	A Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT00627393	PHASE3	COMPLETED	Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)
NCT00770172	PHASE3	COMPLETED	G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
NCT00784368	PHASE3	COMPLETED	A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
NCT00806351	PHASE3	TERMINATED	An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System
NCT00911170	PHASE3	COMPLETED	PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
NCT01307579	PHASE3	COMPLETED	Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
NCT01371656	PHASE3	COMPLETED	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
NCT01560195	PHASE3	UNKNOWN	A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
NCT01611051	PHASE3	COMPLETED	A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
NCT02238873	PHASE3	UNKNOWN	Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
NCT02414581	PHASE3	COMPLETED	Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%